Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kintara Therapeutics, Inc. KTRA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Kintara Therapeutics, Inc. (KTRA) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold.

KTRA Analyst Ratings

Buy
4
Ratings
3 Buy
1 Hold
Based on 4 analysts giving stock ratings to Kintara Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
3 75%
Hold
1 25%
75%
Buy
3 analysts
25%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

LBPH
LBPH
Longboard Pharmaceuticals, Inc.
$59.98
+0.00%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.77
+0.54%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 DMAC
DMAC
DiaMedica Therapeutics Inc.
$6.58
+0.61%
 SCPH
SCPH
scPharmaceuticals Inc.
$5.67
+0.00%
 MIST
MIST
Milestone Pharmaceuticals Inc.
$2.20
+8.37%
 ONCY
ONCY
Oncolytics Biotech Inc.
$1.10
+7.84%
 MCRB
MCRB
Seres Therapeutics, Inc.
$8.84
+2.67%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message